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Abstract
Background: Protein microarrays represent an emerging class of proteomic tools to investigate multiple
protein-protein interactions in parallel. A sufficient proportion of immobilized proteins must maintain an
active conformation and an orientation that allows for the sensitive and specific detection of antibody and
ligand binding. In order to establish protein array technology for the characterization of the weak
interactions between leukocyte membrane proteins, we selected the human leukocyte membrane protein
CD200 (OX2) and its cell surface receptor (hCD200R) as a model system. As antibody-antigen reactions
are generally of higher affinity than receptor-ligand binding, we first analyzed the reactivity of monoclonal
antibodies (mAb) to normal and mutant forms of immobilized CD200R.
Results: Fluorescently labelled mAb DX147, DX136 and OX108 were specifically reactive with
immobilized recombinant hCD200R extracellular region, over a range of 0.1–40 µg ml-1 corresponding to
a limit of sensitivity of 0.01–0.05 femtomol per spot. Orientating hCD200R using capture antibodies,
showed that DX147 reacts with an epitope spatially distinct from the more closely related DX136 and
OX108 epitopes. A panel of soluble recombinant proteins with mutations in hCD200R domain 1 produced
by transiently transfected cells, was arrayed directly without purification and screened for binding to the
three mAb. Several showed decreased binding to the blocking mAb DX136 and OX108, suggesting close
proximity of these epitopes to the CD200 binding site. Binding of hCD200 to directly immobilized rat,
mouse, and hCD200R was achieved with multimeric ligands, in the form of biotinylated-hCD200 coupled
to FITC-labelled avidin coated beads.
Conclusion: We have achieved sensitive, specific and reproducible detection of immobilized CD200R
with different antibodies and mapped antigenic epitopes for two mAb in the vicinity of the ligand binding
site using protein microarrays. We also detected CD200 binding to its receptor, a low affinity interaction,
using beads presenting multivalent ligands. Our results demonstrate the quantitative aspects of protein
arrays and their potential use in detecting simultaneously multiple protein-protein interactions and in
particular the weak interactions found between leukocyte membrane proteins.
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Protein-protein interactions are fundamental to biologi-
cal processes and their analysis is essential for the under-
standing of cellular pathways. Given the complexity and
the dynamic range of the proteome, estimated at 107 pro-
teins, the elucidation of protein interactions requires the
development of comprehensive, high-throughput pro-
teomic methods that allow quantification of multiple pro-
teins simultaneously [1,2]. The development of protein
microarrays represents an attractive new high-throughput
technology platform. It involves the printing of ordered
arrays of biomolecules onto a solid surface in miniatur-
ized format that allows for the simultaneous determina-
tion of multiple interactions using small amounts of
samples within a single experiment. The basic principles
for highly sensitive "microspot" ligand-binding assays
were described by Ekins [3,4] who proposed the "ambient
analyte theory" and showed that microspots containing
small amounts of capture molecules were able to detect
low analyte concentrations with very high accuracy and
sensitivity. Since then, miniaturized protein arrays are
emerging as one of the most powerful proteomics tools
but their application is far more complex [5] than the
DNA microarrays (reviewed in [6-8]) due to structural
complexity and heterogeneity of proteins, including their
post-translational modifications. Binding of the proteins
onto the solid surface of an array must maintain tertiary
structure sufficient for functions such as receptor-ligand
binding or antibody reactivity. Chemically derivatized
microarray surfaces [9,10] or the use of mAb [11,12] have
been shown to maintain protein functionality, thus
increasing the potential for successful application of
microarray technology in proteomics.
The study of leukocyte membrane protein interactions
provides a particular need because of the large number of
interactions yet to be defined [13,14] and a technical chal-
lenge as these interactions are often of very low affinity
with KD in the range 1–200 µM [15,16]. Although weak,
these interactions are important in the context of leuko-
cytes interacting with other cells as illustrated by all the
functional data on the interaction of CD8 with MHC
Class II (KD = 200 µM) [17]. The proteins involved usually
contain folded domains, the most common type belong-
ing to the immunoglobulin superfamily (IgSF) [13]. Such
domains often interact through large faces of the proteins
and require proper folding [18,19]. When measuring low
affinity interactions, misleading results can be obtained
from unfolded or aggregated materials which are not
really a problem when dealing with high affinity interac-
tions such as with cytokines and their receptors, or
between proteins and linear epitopes such as lectins and
carbohydrates. In addition many leukocyte surface pro-
teins are heavily glycosylated and the oligosaccharides,
even if not directly involved in binding, may be important
in maintaining biologically active proteins [20]. Thus, in
applying the protein microarray technology to the study
of leukocyte surface protein interactions, it is imperative
that the proteins are expressed in eukaryotic systems to
ensure correct disulphide bond formation and post-trans-
lational modifications.
In this study we chose a well characterized interaction
between CD200 (previously called OX2) and its receptor
CD200R (reviewed in [21]) as a model system to devise a
high throughput protein array method for characteriza-
tion of the interactions between leukocyte surface pro-
teins. CD200 is a widely distributed membrane protein
with two extracellular IgSF domains and a short cytoplas-
mic region unlikely to signal. It interacts with a receptor
(CD200R) expressed mostly on myeloid cells, which also
has two extracellular IgSF domains but a longer cytoplas-
mic region with several tyrosine residues that can be phos-
phorylated [22]. Functional analysis suggests that the
leukocyte CD200 protein can mediate a down-regulatory
signal to myeloid cells through the inhibitory CD200R.
Thus the CD200 null mice have an increased susceptibil-
ity to autoimmune disease induction and myeloid cells
expressing CD200R are more activated [23]. CD200 and a
viral homologue found in Kaposi sarcoma virus, when
expressed at the cell surface, gave inhibition of production
of inflammatory cytokines from activated macrophages
[24]; and targeting the CD200-CD200R interaction with
agonistic mAb or CD200-Fc fusion proteins in vivo amel-
iorates autoimmunity in disease models [25,26].
Protein arrays can be divided into two major classes: 'for-
ward phase' if the analytes are captured from solution; or
'reverse phase' if the analytes are bound directly to the
solid phase [27]. In forward phase protein microarrays, a
bait molecule such as an antibody is immobilized onto a
solid support to capture the analytes which can be pro-
teins in purified form, or in complex solutions such as cell
lysates [12] or tissue samples [27,28]. The bound analytes
are detected either by direct labelling or via a secondary
antibody. In reverse phase arrays, the analytes (typically
purified proteins or cell lysates) are directly immobilized
on the solid phase and antibodies or interacting proteins
are applied in solution phase. The analytes can be labelled
directly or detected using tags and signal amplification.
We have used the forward phase approach in the mapping
of antigenic epitopes of hCD200R where different anti-
bodies were immobilized on epoxy coated glass slides,
incubated with the hCD200R analyte and detected with
fluorescently labelled anti-CD200R antibodies. We have
applied reverse phase arrays to three different purposes: -
to test the reactivity of the fluorescently labelled mAb with
directly immobilized hCD200R protein, -to map epitopes
located near the ligand binding site using arrayed mutantPage 2 of 12
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rescently labelled mAb that block ligand-receptor interac-
tions and -to detect the low affinity binding of
immobilized CD200R to the multivalent CD200 ligand
presented on fluorescently labelled beads. Our study
extends the use of protein microarrays to the detection of
transient cell surface protein interactions, which are of
lower affinity than the reported cytokine arrays [29,30].
Results and discussion
Quantitative binding of DX147, DX136 and OX108 mAb to 
human CD200R
Purified, soluble recombinant hCD200R protein, engi-
neered with domains 3 and 4 of rat CD4 as an antigenic
tag (hCD200R-CD4d3+4) [31] was directly immobilized
at different concentrations on epoxy-coated glass slides, in
a reverse phase array as illustrated schematically (Fig. 1A).
The hCD200R array was tested for reactivity with three dif-
ferent mAb: DX147, and two previously reported [31]
mAb DX136 and OX108 able to block ligand binding.
Controls on the arrays included recombinant mouse
CD200R-CD4d3+4 protein (mCD200R) [31] and rat
CD4d3+4. Figure 1B and 1C illustrate the strong and spe-
cific binding of all three fluorescently labelled mAb to
hCD200R, as demonstrated by minimal reactivity with
rCD4 (rat CD4d3+4) and lack of cross-reaction with
mCD200R. DX147 gave the strongest labelling with linear
binding from 0.08 to 20 µg ml-1 mAb, reaching the upper
limits of detection under the optimized voltage settings
(65,000 units of green fluorescence) at 40 µg/ml (Fig. 1B).
Binding of DX136 was linear over the full range of con-
centrations with a maximum binding of 48,000 units.
OX108 bound more weakly, reaching a maximum value
of 32,000 units. Sensitivity of detection, defined as two-
fold binding above background, was estimated as the low-
est hCD200R-CD4d3+4 concentration tested (0.08 µg ml-
1) for DX136. A three-fold signal to noise ratio was
achieved for DX147 at that concentration suggesting that
sensitivity of detection was closer to 0.05 µg ml-1. For
OX108, the limit of sensitivity was estimated at 0.3 µg ml-
1. Thus DX147, DX136 and OX108 were able to detect 0.5
pg, 0.8 pg and 3.0 pg of hCD200R per spot respectively
estimating a spot volume of 10 nl. The limit of sensitivity
achieved was therefore between 8 and 50 attomol, assum-
ing a molecular weight of 60,000 for hCD200R-CD4d3+4
protein. The amounts of human and mouse CD200R-
CD4d3+4 and rCD4d3+4 protein on the microarray spots
were similar as visualized by the red fluorescence of OX68
mAb recognising the CD4 tag present in each of the
recombinant proteins (Fig. 1B and 1D). This indicates
that the amount of protein detected is proportional to the
amount arrayed in each spot and is highly reproducible.
The limit of sensitivity of protein detection with Alexa
647-OX68 was approximately 0.3 µg ml-1, corresponding
to 50 attomol of CD200R-CD4d3+4 proteins. Although
not all molecules will be in a proper orientation for equal
access to both anti-CD200R and anti-CD4, as illustrated
in Fig. 1A, our results suggest that on average, there is a
good correlation between the amount of specific antibody
bound and the amount of protein arrayed.
Orientation via antibody immobilization for epitope 
mapping on human CD200R
We used forward phase protein microarrays to define the
epitopes of hCD200R recognized by the three mAb intro-
duced in the previous section. Serial dilutions of DX147,
DX136 and OX108 mAb and the control CD4 mAb OX68
were directly immobilized on epoxy-coated glass slides as
shown (Fig. 2A). The mAb arrayed act as capture reagents
for hCD200R, used at a concentration of 20 µg ml-1. Each
capture mAb binds to a different epitope on the
hCD200R-rCD4d3+4 recombinant protein, thus orientat-
ing the protein on the array in a conformation that per-
mits or restricts access to the same panel of mAb, used as
detection reagents (Fig. 2A). Visual observation (Fig. 2B)
and quantitative analysis (Fig. 2C) showed that DX147
reacts with an epitope spatially distinct from the more
closely related DX136 and OX108 epitopes. As expected,
OX68 is the most suitable capture mAb, as it binds the
common CD4 tag allowing exposure of the two extracel-
lular domains of hCD200R and binding of all three spe-
cific mAb. When the detection mAb is the same as the
capture mAb, no significant binding above background is
observed (Fig. 2C). DX147 binds specifically to
hCD200R-CD4d3+4 orientated via OX68 and DX136
(16,021 and 12,570 green fluorescence units respectively
at 80 µg ml-1 of capture mAb), but not via OX108 or via
itself. This is an indication that the binding epitopes for
DX136 and DX147 are dissimilar. DX136 in turn, binds
well to hCD200R-CD4d3+4 immobilized on OX68
(13,954 units of green fluorescence at 80 µg ml-1) and to
a lesser degree to hCD200R-CD4d3+4 immobilized on
DX147 (2,647 units), while not at all to hCD200R cap-
tured by OX108 (496 units). These data indicate that the
DX136 epitope is spatially distinct from the DX147
epitope, but in close proximity to the OX108 epitope. This
conclusion is substantiated by the lack of binding of
OX108 mAb to hCD200R-CD4d3+4 captured on DX136.
Orientating hCD200R via mAb OX68 allows for specific
binding of all three anti-human CD200R mAb, in a linear
fashion with limits of sensitivity of about 5 µg ml-1 of
immobilized mAb. The maximum amount of signal was
obtained by capturing hCD200R with 80 µg ml-1 of mAb
OX68 and was equivalent to that observed by directly
immobilizing approximately 10 µg ml-1 hCD200R. OX68
is therefore the best mAb for capturing the chimaeric
hCD200R-CD4 protein for optimal detection of
hCD200R epitopes.Page 3 of 12
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Quantitative binding of mAb to hCD200R-CD4d3+4. (A). Scheme illustrating a reverse phase microarray in which puri-
fied CD200R proteins were immobilized and then screened with fluorescent mAb specific for hCD200R or for the antigenic 
rCD4 tag (OX68) of the hybrid recombinant protein.(B). Typical microarray shows binding of OX68 mAb (red) to control 
proteins or the overlapping binding of hCD200R mAb and OX68 (yellow) to immobilized human CD200R.(C). Shows the 
green fluorescence intensity of each spot for all four replicates (mean ± SEM).(D). Shows red fluorescence intensity due to 
binding of OX68 mAb using data in left panel for DX147 (similar levels were found with the other mAb). Serial two-fold dilu-
tions of purified, soluble, recombinant human and mouse CD200R-CD4d3+4 proteins, and of control rat CD4d3+4 were 
arrayed onto epoxy-coated microscope slides. Each protein dilution series was arrayed in 3 rows of 4 spots, ranging in concen-
tration from 40 µg ml-1 (first spot) to 0.08 µg ml-1 (spot 10), with control spotting buffer containing 0.5 mg ml-1 BSA in the last 
two spots. All arrays were performed in quadruplicate and a representative set is shown in (B). Each slide was incubated for 16 
h at 4°C with a mixture of hCD200R mAb (DX147, DX136 or OX108) labelled with Alexa-555 (indicated as green fluores-
cence measured at 532 nm) and rCD4 mAb (OX68, detecting the antigenic tag and allowing for measurement of recombinant 
protein concentration) labelled with Alexa-647 (red fluorescence measured at 635 nm). At the highest concentrations, the 
hCD200R spots appear either white (saturating conditions) or yellow, due to the combination of green and red signals given by 
the specific binding of the Alexa-555-mAb to hCD200R and Alexa-647-OX68 mAb respectively. Quantitative measurements 
are expressed as mean fluorescence units at 532 nm (green) and 647 nm (red) versus amount of protein arrayed.
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BMC Biochemistry 2005, 6:2 http://www.biomedcentral.com/1471-2091/6/2Analysis of mAb reactivity with hCD200R by orientation via antibody immobilizationFigure 2
Analysis of mAb reactivity with hCD200R by orientation via antibody immobilization. (A). Scheme of one forward 
phase microarray in which purified human CD200R protein was immobilized via OX68 mAb and detected with the DX136 
hCD200R mAb (green fluorescence).(B). Typical microarray shows binding of the hCD200R mAb (green) and OX68 mAb 
(red) to hCD200R immobilized via four different capture mAb.(C). Shows the mean fluorescence intensity ± SEM for each spot 
of all replicates. Serial two-fold dilutions of capture human CD200R mAb OX108, DX136 and DX147 and control rat CD4 
mAb OX68 were arrayed onto epoxy-coated microscope slides. Each mAb dilution series was arrayed in quadruplicate of 2 
rows of 6 spots, ranging in concentration from 80 µg ml-1 (first spot) to 0.16 µg ml-1 (spot 10), with control spotting buffer con-
taining 0.5 mg ml-1 BSA in the last two spots. The whole array was repeated on the slide for a total of 8 replicates per spot. 
Each slide was incubated for 2 h with 20 µg ml-1 of purified recombinant hCD200R-CD4d3+4 protein, prior to incubation with 
Alexa-555-labeled CD200R mAb (DX147, DX136 or OX108) or Alexa-647 control rCD4 mAb (OX68). Quantitative meas-
urements are expressed as mean fluorescence units at 532 nm (green) and 635 nm (red) versus amount of capture mAb 
arrayed.
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Both CD200R and its ligand, CD200 contain two extracel-
lular IgSF domains. The ligand-receptor interaction is
therefore likely to occur in an end-to-end topology,
requiring opposing cell surfaces to come into close prox-
imity [22]. Previous studies have shown that the mem-
brane distal N-terminal domain of CD200 is involved in
binding its receptor [32]. In a recently published study
[33], site directed mutagenesis was employed to map the
ligand-binding domain of human CD200R using the
structure of a typical Ig V domain, that of the human junc-
tional adhesion molecule 1, JAM1 to predict the positions
of out-pointing residues [34]. A panel of mutants was
designed so as to target residues likely to be out-pointing
from predictions of the beta strands of the N-terminal
IgSF domain of hCD200R. The binding sites of CD200
and of the OX108 mAb known to block ligand interaction
to the hCD200R mutants, were shown to be on the GFCC'
face of the N-terminal IgSF domain [33].
The same panel of hCD200R-CD4d3+4 mutant proteins
(Table 1) was analyzed by reverse protein microarrays
(analogous to Fig. 1A) for binding to mAb DX147, DX136
and OX108 in order to map these epitopes. The mutant
proteins were expressed by transient transfection in
serum-free medium, concentrated and arrayed. Purified
human and murine CD200R serving as positive and neg-
ative controls were immobilized at concentrations rang-
ing from 0.08 to 40 µg ml-1. Lack of binding by a specific
mutant or group of mutants is suggestive of the corre-
sponding residues defining the location of the antigenic
epitopes. None of the hCD200R mutants tested had lost
binding to DX147, confirming unpublished data that this
epitope lies, not in the N-terminal domain of CD200R but
in the membrane proximal domain. Some of the mutants
showed increased binding of mAb over the wild type
despite these being normalized with OX68 (e.g. R67,
I71K). This presumably reflects variations in epitope
availability due to direct immobilization of the mutant
proteins on the array, which are less likely to occur in
BIAcore studies where mutants were immobilized via
OX68 mAb [33]. Thus our data analysis was focused on
mutants with major impairment in binding activity. Nine
of the mutants showed reduced binding to either DX136
and/or OX108 mAb, relative to wild type hCD200R, as
represented graphically in Figure 3. One mutant illus-
trated (E75K) did not affect binding in a significant man-
ner. The position of these mutants is shown on the model
of the N-terminal domain of hCD200R, based on a typical
IgSF domain of similar size (Fig. 4). Panel A shows the
mutants affecting CD200 binding, as reported in [33].
These mutants were mostly in the GFCC' face and in par-
ticular the F and C strands. Panel B shows the mutants
with reduced binding to DX136 and/or OX108. It is
immediately noticeable that mutants within the F and C
strands also appear to have lost binding to DX136 and
OX108 mAb, suggesting close proximity of these epitopes
to the CD200 binding site, in agreement with the ligand
blocking activity of these mAb. However, the key residues
were not identical as shown by the differing effects of the
mutants I71K and R67D. Furthermore, the microarray
study confirms the results obtained by individual analysis
of each mutant by surface plasmon resonance in terms of
residues involved in OX108 binding; the most critical
amino acid appears to be R67 located in the B-C loop
[33]. The finding of mutants that had apparently gained
CD200R mAb binding activity compared to the OX68
mAb recognising the CD4 tag, shows that spotting can
have effects not seen by indirect methods such as the
Table 1: hCD200R protein mutants tested. Mutant proteins were 
constructed as described in [33], expressed by transient 
transfection in serum-free medium, concentrated and 
immobilized on epoxy-derivatized slides. The predicted 
positions of the residues are located in the modelled V-like N-
terminal IgSF domain unless noted otherwise (C domain).
# Mutant Name Predicted Position
1 Wild-type
2 D30K* N-term
3 K40D* A strand
4 L42E* A strand
5 E44K* A strand
6 E44A A strand
7 E44D* A strand
8 M53K A-B loop
9 N56D B strand
10 P62F B strand
11 I64S* B-C loop
12 R67D B-C loop
13 I71K C strand
14 T73R C strand
15 E75K C strand
16 R79E C-C' loop
17 Q81K C-C'
18 S83D* C" strand
19 E97K C" strand
20 T106D* D strand
21 D116K* D-E loop/ E strand
22 A123D E strand
23 Y129D F strand
24 R131E F strand
25 I133K F strand
26 D138K* F-G loop
27 R143D* F-G loop
28 H146D G strand
29 Q148E* G strand
30 L150D* G strand
31 T156N* A strand C domain
32 N160D A-B loop C domain
33 A175D* B-C loop C domain
* Mutants expressed with concentration below sensitivity threshold, 
for which no antibody binding data could be derived.Page 6 of 12
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between available BIAcore data and microarray data. Thus
this method provides a rapid high throughput method to
identify the rare mutants that affect antigenic activity that
can then be characterised further e.g. by BIAcore analysis.
Reactivity of human, rat and mouse CD200R with 
multimeric human CD200
The interaction of human CD200 with its receptor
hCD200R is of low affinity, with a KD of ~0.5 µM at 37°C
and t1/2 of 7 s [24], typical of the interaction of many
leukocyte membrane proteins [15]. Such an interaction
could not be detected when immobilized hCD200R was
incubated with fluorescently labelled purified monomeric
hCD200 protein (data not shown). In order to develop
leukocyte membrane receptor-ligand microarray assays,
high avidity detection reagents are required. Recombinant
hCD200 protein was constructed by linking the extracel-
lular domains of human CD200 with domains 3 and 4 of
rat CD4 (CD4d3+4) as an antigenic tag. This construct
contains a 19 amino acid sequence at the C-terminus of
the protein, which can be enzymatically biotinylated on a
specific lysine residue using the E. coli BirA enzyme [35].
Expression of the construct was demonstrated by inhibi-
tion of a rat CD4 ELISA using OX68 mAb. The recom-
binant protein bound the mAb OX104 (mouse anti-
human CD200), indicating that it was antigenically
active, as assessed by BIAcore analysis (data not shown)
and its biotinylation was confirmed by streptavidin bind-
ing. The biotinylated hCD200-CD4d3+4 protein or the
control CD4d3+4 protein were attached to avidin-coated
FITC-fluorescent beads via their biotin tag, thus creating
polyvalent CD200 and control reagents. These beads were
used to detect specific binding of CD200 to human,
mouse and rat CD200R proteins arrayed directly on
epoxy-coated glass slides (Fig. 5A). Additional controls
included rCD4d3+4 protein arrayed on the slide and
tested for reactivity with both types of beads. Strong bind-
ing of hCD200-beads to all three CD200R proteins was
observed (Fig. 5B and 5C) indicating that the proteins
immobilized on the glass surface had retained their capac-
ity to bind ligand with maximum mean values of 63,500
green fluorescence units for rat CD200R (saturating),
43,600 for mouse CD200R and 23,800 for human
Mapping of antigenic epitopes on hCD200R mutantsFigure 3
Mapping of antigenic epitopes on hCD200R mutants. The hCD200R mutants described in Table 1 and produced by 
transient transfection were arrayed (reverse phase) and tested for specific binding to mAb DX147, DX136 and OX108 and for 
reactivity with OX68 to quantify the relative amount of protein in each sample as described in Methods. Results for a panel of 
10 mutants are plotted as percent antibody binding normalized to the wild type, non-mutated hCD200R protein (WT) values.
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actually visualizing the small fluorescent beads. Binding
was detected at concentrations of receptors ranging from
approximately 5 to 40 µg ml-1 corresponding to 1–8 fem-
tomol per spot on the microarray. The non-specific bind-
ing of hCD200-beads to immobilized rCD4 protein was
negligible (Fig. 5B and 5C) and control CD4d3+4 beads
did not react with any of the arrayed proteins (data not
shown). The multivalent hCD200-beads cross-reacted
with rat and mouse CD200R as expected, as BIAcore anal-
ysis has shown that hCD200 interacts with human, rat
and mouse CD200R with affinity constants within a log of
Mapping of DX136 and OX108 epitopes on the N-terminal domain of human CD200RFigure 4
Mapping of DX136 and OX108 epitopes on the N-terminal domain of human CD200R. (A). The mutants giving 
complete or nearly complete inhibition of CD200 binding, determined by BIAcore analysis, are indicated with red circles 
(<35% binding compared to non-mutated WT hCD200R protein), whereas those giving partial effects (35–70% binding) are 
depicted in orange. Data from [33].(B). The mutants giving severe inhibition (<35% compared to WT) of OX108 and DX136 
mAb binding, as determined by microarray analysis, are depicted in blue and yellow respectively. Dark green circles represent 
mutants that severely impaired both OX108 and DX136 mAb binding. Mutants partially affecting DX136 binding (35–50%) are 
shown in pale yellow. Mutants that severely affect DX136 binding (35% binding or less) but have only a partial effect on OX108 
binding (50%) are represented in pale green. Open circles depict mutants that did not affect the binding of CD200, OX108 or 
DX136 mAb. The CD200R model is based on a typical Ig V domain from the human junctional adhesion molecule-1 (JAM1) 
[34]. The beta sheets are labelled with the GFC face orientated in front and the BED face behind.Page 8 of 12
(page number not for citation purposes)
BMC Biochemistry 2005, 6:2 http://www.biomedcentral.com/1471-2091/6/2each other [31]. Sensitivity of detection, defined as two-
fold binding above background was achieved with con-
centrations of 5 µg ml-1 for rat CD200R and 10 µg ml-1 for
human and murine CD200R. This corresponds to 1–2
femtomol of immobilized receptors interacting with the
multimeric human CD200 ligand.
Conclusion
In order to study interactions of leukocyte membrane pro-
teins using high throughput microarray techniques, it was
essential that the proteins be immobilized at low concen-
trations and in a biologically active form. It is critical that
weak interactions between leukocyte membrane proteins
be detected without interference by the anomalous bind-
ing due to denatured proteins, which is more of a contrib-
uting factor in the study of low affinity interactions. We
first established that recombinant CD200R proteins could
be immobilized directly in reverse phase arrays, in a con-
formation capable of reacting with three different mAb.
We then demonstrated that recombinant mutant
hCD200R proteins produced in transient expression sys-
tems were present in sufficient amounts to be immobi-
lized directly and tested for reactivity with specific mAb,
permitting mapping of epitopes. These data show that
high throughput analysis of cell surface proteins can be
achieved in reverse phase arrays using recombinant pro-
teins derived from transient transfectants in a non-puri-
fied form. We also used forward phase arrays for
competitive analysis of antibodies and mapping of their
epitopes. This approach is valuable for rapidly screening
antibody specificities and assessing protein orientation
needed for optimal presentation of immunogenic
determinants.
We also showed that binding of CD200 ligand to its cell
surface receptor can be achieved by increasing the avidity
of the reaction via coupling of the biotinylated
recombinant CD200 protein to fluorescently labelled avi-
din coated beads. The fluorescent beads offer an efficient
technology for the analysis of low affinity interactions typ-
ical of those observed for leukocyte membrane proteins
and many other cellular proteins.
Binding of multimeric CD200 ligands to CD200R proteinsF gure 5
Binding of multimeric CD200 ligands to CD200R proteins. (A). Diagram of the reverse phase array depicting immobi-
lized CD200R interacting with the multivalent bead ligand.(B). A representative microarray set showing binding of hCD200 
beads to CD200R-CD4d3+4 proteins, but not control rat CD4.(C). Mean fluorescence intensity ± SEM of all four sets is 
shown versus receptor protein concentration arrayed. Serial two-fold dilutions of purified, soluble, recombinant human, mouse 
and rat CD200R-CD4d3+4 proteins, and of control rat CD4 were arrayed onto epoxy-coated microscope slides. Each recep-
tor protein dilution series was arrayed in 3 rows of 4 spots, ranging in concentration from 40 µg ml-1 (first spot) to 0.08 µg ml-
1 (spot 10), with control spotting buffer containing 0.5 mg ml-1 BSA in the last two spots. Only the first 8 dilutions (2 rows) are 
shown in (B) and analyzed in (C). All arrays were performed in quadruplicate. All receptors were arrayed on the same slide, 
which was incubated for 16 h at 4°C with polyvalent human CD200-CD4d3+4 FITC-fluorescent beads. At the highest concen-
trations, the hCD200R spots appear white (saturating conditions). Quantitative measurements are expressed as fluorescence 
units at 532 nm (green) versus amount of protein arrayed.
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Materials
Monoclonal antibodies (mAb) DX147 (rat IgG1), and
DX136 (rat IgG2a) to human CD200R were generously
given by DNAX Research Institute (Palo Alto, CA). The
mAb OX108 (mouse IgG1) to human CD200R [31] and
OX68 (mouse IgG1) to rat CD4 domains 3 and 4
(rCD4d3+4) have been described previously [36].
Recombinant proteins
The soluble biotinylated forms of human, mouse and rat
CD200R were produced as described [22,31,36]. Briefly,
the entire extracellular region of human, mouse or rat
CD200R was amplified by PCR and cloned in the pEF-
BOS-CD4d3+4bio-XB vector [35]. These constructs were
then subcloned into the expression vector pEE14, and sta-
bly secreting CHO.K1 cell lines were established [37].
Human, mouse or rat CD200R-CD4d3+4 proteins were
purified from the tissue culture medium by immunoaffin-
ity chromatography with OX68 mAb-Sepharose 4B that
recognizes the CD4 protein tag [36]. Prior to use, the puri-
fied CD200R proteins were fractionated by gel filtration
on Superdex S-200 (Pharmacia, Uppsala, Sweden) to
exclude protein aggregates. The soluble, biotinylated form
of human CD200 was produced in an identical fashion,
by subcloning the amplified extracellular region of
human CD200 [38] using XbaI/SalI digestion to the pEF-
BOS-CD4d3+4bio-XB vector [36]. This construct was used
to transfect HEK293T cells using the calcium phosphate
method. The protein expressed was enzymatically bioti-
nylated and used to generate multivalent binding reagents
by coupling to avidin-coated fluorescein isothiocyanate
(FITC)-loaded beads (Spherotech Inc., Libertyville, IL) as
described previously [35].
Mutants of human CD200R (hCD200R) were prepared as
described [33]. Briefly, the mutations were introduced by
site directed mutagenesis using PCR and two mutagenic
oligonucleotides into a construct comprising the extracel-
lular domains of human CD200R together with domains
3 and 4 from rat CD4 (CD4d3+4) as an antigenic tag. The
mutants were transiently expressed in HEK 293T cells
using X-VIVO 10 media (BioWhittaker, Nottingham),
concentrated about 10 fold and levels of expressed protein
quantified by ELISA. This media contains 1 mg ml-1 BSA
so after concentration the final protein concentration is
around 10 mg/ml.
Antibody labelling
Purified antibodies were dialysed against PBS prior to
labelling with Alexa Fluor 555 or Alexa Fluor 647 fluores-
cent amine-reactive dyes using the Molecular Probes Mon-
oclonal Antibody Labelling Kits (Cat. No. A-20186 and A-
20187) and according to the manufacturer's instructions
(Molecular Probes, Invitrogen Ltd.). Labelling reactions
were carried out using 100 µg of IgG and yielded labelled
proteins ranging in concentration from 1 to 4 × 10-6 M.
The degree of conjugation was estimated at 2–4 moles of
dye per mole protein. Labelled antibodies were stable for
up to 2 months at 4°C.
Preparation of microarrays
Protein solutions to be arrayed were prepared in 96 well
plates and 12 µl aliquots were transferred to single wells
of Genetix 7020, 384-well plates (Genetix Ltd, New Mil-
ton, UK). Concentrations tested ranged from 0–80 µg/ml
and all dilutions were performed in Protein Array Spot-
ting Solution (Genetix) with the addition of 0.5 mg/ml
BSA and 0.02% NaN3. A QArrayMini microarray printer
(Genetix) was used to apply the protein solutions onto
epoxy-coated microscope slides using 300 µm solid
tipped tungsten microarraying pins (Genetix). Prelimi-
nary experiments established the printing conditions with
fluorescently labeled OX68 mAb. Of several types of slides
tested, the epoxy-coated ones were the best in terms of
spot morphology, cost and reproducibility and were used
in all subsequent experiments.
Most array designs were performed using 8 pins to obtain
spots with a 440 µm diameter and centre-to-centre spot
spacing of 700 µm in both directions. Source plates were
kept at 8°C, and a 65% average internal humidity was
maintained. After printing, the slides were left in the array-
ing chamber for 30–60 minutes under the same condi-
tions. The slides were then washed using the Protein Array
Processing Kit (Genetix Ltd; stored at 4°C and the solu-
tions supplemented with 0.02 % NaN3) by inversion for
1 min in Clean Up Buffer (Genetix) to remove unbound
proteins and incubation for 30 min in Blocking Buffer.
Slides were washed 3 times in PBS, once in H2O to remove
excess salt and dried using an air brush, and stored at 4°C,
with desiccant in a sealed slide box. Preliminary experi-
ments were done by forward phase arrays to establish
optimal conditions. OX68 mAb (100 µg ml-1 to 20 µg ml-
1) was immobilized, incubated with rat CD4 at 5 µg ml-1
0.1 mg ml-1 BSA, washed and incubated with labeled W3/
25 mAb (5 µg/ml) and linearity of detection demon-
strated. Specificity was also shown by the fact that OX68
was not reactive with CD4 immobilised on OX68 and vice
versa.
Labelling of microarrays
Slides were placed in hybridization chambers (Corning
Incorporated, UK) and the humidification wells filled.
LifterSlips, (Erie Scientific, Portsmouth, USA) were placed
gently over the marked boundaries of the arrays and the
binding reagent (25–70 µl) was introduced with a micro-
pipette. In experiments where CD200R-CD4 hybrid pro-
teins (including the mutant studies) were arrayed, Alexa-
555 anti-CD200R antibodies (mAb DX147, DX136 orPage 10 of 12
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of specific antibody bound and Alexa-647-CD4 mAb
(OX68 5–10 µg ml-1) was included to assess the amount
of hybrid protein present. In experiments where capture
antibodies were arrayed (Fig. 2), a 2 h incubation with
purified protein, such as CD200R-CD4d3+4 or CD4d3+4
at 20 µg ml-1, was performed prior to incubation with the
detection antibodies. In the experiments detecting CD200
(ligand) binding to immobilized CD200R (Fig. 5), arrays
were incubated with biotinylated hCD200-CD4d3+4
streptavidin-FITC beads. Incubations with detection rea-
gents were carried out for 16 h at 4°C unless otherwise
stated. The slides were immersed upside down in PBS/
0.05% Tween-20, washed thrice with copious amounts of
PBS/Tween-20, alternating shaking up and down under
liquid in the Copeland jar and gentle rocking for 5–10
min each, followed by PBS (twice for 5 min) and a final
H2O rinse. All washes were at room temperature and
repeated following each incubation. After drying the
slides with an air brush, the arrays were scanned using a
GenePix4000B microarray scanner (Axon Laboratories,
Palo Alto, CA) scanner using 532 nm and 635 nm lasers
using the GenePix Pro 5.0 (Axon Laboratories) software.
The PMT values were 720 and 1000 (532 nm and 635 nm
respectively) for Figure 1, 780 and 950 for Figure 2, 900
and 1000 for Figure 3 and 850 for Figure 5 (532 nm only).
Data analysis
All samples were tested in quadruplicate and all experi-
ments repeated several times. The amount of antibody or
ligand bound to the arrayed proteins and the amount of
protein present in each spot were determined by compar-
ing the fluorescence intensities read at 532 and 635 nm.
Extraction of spot intensity data was performed using
GenePix Pro 5.0 (Axon Laboratories) and ScanArray
Express (Perkin Elmer). The background, calculated as the
median of pixel intensities from the local area around
each spot, was subtracted from the mean pixel intensity
within each spot. To graphically represent the data, the
values of the background-subtracted signal intensities
were plotted against the known concentration of the
protein spotted in the array. Sensitivity of detection for
each spot was defined as a signal to noise ratio (S/N) of
two-fold above background. S/N was calculated as: S/N =
(background-subtracted median signal intensity) / (stand-
ard deviation of background signal intensity).
In the case of the mutant hCD200R proteins generated
from culture supernatants of transient transfections,
where protein concentration is unknown, the back-
ground-subtracted values for both 532 and 635 nm-signal
intensities were corrected for internal protein signal by
subtracting the corresponding value of a "mock transfect-
ant" spot. The corrected values for the red channel (repre-
senting the amount of protein assessed from the CD4
content) were normalised to 100% with respect to the
wild-type hCD200R transient transfection sample. All
hCD200R mutants with red channel values below 50%
were assumed to contain insufficient amount of protein
and were excluded from the analysis. The green channel
background-subtracted, "mock"- transfectant corrected
values (G) were divided by the corresponding red channel
ones (R) to correct for variations in the amount of
expressed protein contained in each individual spot (G/R
ratio). Finally, the G/R ratio was normalized to 100% with
respect to the hCD200R-CD4d3+4 wild-type protein,
before graphical representation.
List of abbreviations
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human CD200 receptor; mCD200R, mouse CD200 recep-
tor; rCD200R, rat CD200 receptor; SPR, surface plasmon
resonance; WT, wild type.
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